Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GIOVANNA M DA SILVA SOUTHWICK

Allopathic & Osteopathic Physicians Colon & Rectal Surgery

NPI
1770745028
CMS profile
125454
Location
WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,612.71

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $1,000.00 1
Travel and Lodging $994.31 5
Food and Beverage $609.66 8
Gift $8.74 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
INTUITIVE SURGICAL, INC. $1,393.58 9
Davol Inc. $1,000.00 1
Medtronic, Inc. $199.98 4
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.15 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GIOVANNA M DA SILVA SOUTHWICK

NPI 1770745028 · CMS profile ID 125454

Allopathic & Osteopathic Physicians / Colon & Rectal Surgery

WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770745028?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GIOVANNA M DA SILVA SOUTHWICK, NPI 1770745028, CMS profile ID 125454. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770745028?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GIOVANNA M DA SILVA SOUTHWICK, NPI 1770745028, CMS profile ID 125454. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770745028?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GIOVANNA M DA SILVA SOUTHWICK, NPI 1770745028, CMS profile ID 125454, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1770745028?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $2,612.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $14.1611/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119478809 CMS
Medtronic, Inc. $123.3309/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119478807 CMS
Medtronic, Inc. $19.1607/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119478805 CMS
INTUITIVE SURGICAL, INC. $110.1105/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137102457 CMS
INTUITIVE SURGICAL, INC. $37.0905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137149908 CMS
INTUITIVE SURGICAL, INC. $34.5905/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137258377 CMS
INTUITIVE SURGICAL, INC. $19.0004/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137163928 CMS
INTUITIVE SURGICAL, INC. $157.0004/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137261200 CMS
INTUITIVE SURGICAL, INC. $318.8504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137196981 CMS
INTUITIVE SURGICAL, INC. $8.7404/10/2024 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137281490 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.1502/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153639046 CMS
Davol Inc. $1,000.0002/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127651185 CMS
INTUITIVE SURGICAL, INC. $19.0002/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137126025 CMS
INTUITIVE SURGICAL, INC. $689.2002/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137148976 CMS
Medtronic, Inc. $43.3302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119478803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.42 2
PY2020 $220.00 1
PY2021 $5,291.15 5
PY2022 $16,303.53 17
PY2023 $7,818.14 24
PY2024 $2,612.71 15
PY2025 $357.46 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,345.50 7
PY2024 Principal investigator $37,270.82 15
PY2023 Principal investigator $20,802.60 6
PY2022 Principal investigator $27,782.21 8
PY2021 Principal investigator $117,673.37 17
PY2020 Principal investigator $15,664.23 14
PY2019 Recipient $108.18 2
PY2019 Principal investigator $17,505.47 558

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $76,263.80 12/23/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816789751
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15.70 10/12/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816765841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $96.20 10/12/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816765851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.10 10/12/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816765861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15.70 10/06/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816764889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $96.20 10/06/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816764897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.10 10/06/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816764907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $629.75 10/02/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816764083
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $629.75 09/24/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816761729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23.92 05/25/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816727657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $153.92 05/25/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816727667
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $49.28 05/25/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816727677
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,029.46 05/24/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816727307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17.40 02/22/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816691685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $96.84 02/22/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816691695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36.90 02/22/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816691705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,402.35 01/18/2021 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS No dispute reported 06/30/2026 816681035